Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Concord Biotech's FCF Margin % or its related term are showing as below:
BOM:543960'
s FCF Margin % Range Over the Past 10 Years
Min: -6.18 Med: 11.3 Max: 18.01
Current: 16.28
During the past 7 years, the highest FCF Margin % of Concord Biotech was 18.01%. The lowest was -6.18%. And the median was 11.30%.
BOM:543960's FCF Margin % is ranked better than 87.26% of 950
companies
in the Biotechnology industry
Industry Median: -82.715
vs BOM:543960: 16.28
Concord Biotech FCF Margin % Related Terms
Concord Biotech FCF Margin % Historical Data
* Premium members only.
The historical data trend for Concord Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543960 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Concord Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Concord Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Biotech (BOM:543960) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Concord Biotech and its competitors. According to the industry distribution chart, Concord Biotech ranks #121 out of 950 companies in the Biotechnology industry, placing it in the top 12.7%.
Is Concord Biotech's FCF Margin % too high?
Concord Biotech's current FCF Margin % is 0.00%. Based on the distribution chart, Concord Biotech ranks #121 out of 950 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Concord Biotech has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #121 out of 950 companies for FCF Margin %. This places Concord Biotech in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Concord Biotech and its competitors. Concord Biotech's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,666.31, compared to a current price of ₹1,257.00 — trading 24.6% below its estimated fair value. The current FCF Margin % is 0.00%. Concord Biotech's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,257.00 is trading 24.6% below its estimated GF Value™ of ₹1,666.31.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
FCF Margin %: 0.00%
GF Value™: ₹1,666.31 vs. price of ₹1,257.00 (24.6% below fair value)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
68GF Score
Get the complete analysis for BOM:543960
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
